4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) have been given a consensus rating of “Moderate Buy” by the eleven analysts that are presently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and eight have given a buy recommendation to the company. The average 1 year target price among brokerages that have covered the stock in the last year is $28.70.

A number of research analysts recently issued reports on FDMT shares. Morgan Stanley upgraded 4D Molecular Therapeutics from an “underweight” rating to an “equal weight” rating in a report on Friday, November 7th. Wall Street Zen raised 4D Molecular Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, November 15th. Barclays decreased their target price on 4D Molecular Therapeutics from $38.00 to $33.00 and set an “overweight” rating for the company in a report on Tuesday, November 11th. Weiss Ratings reiterated a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a report on Wednesday, October 8th. Finally, Roth Capital reduced their price objective on shares of 4D Molecular Therapeutics from $44.00 to $38.00 and set a “buy” rating on the stock in a research report on Tuesday, August 12th.

4D Molecular Therapeutics Stock Performance

NASDAQ:FDMT opened at $10.99 on Friday. 4D Molecular Therapeutics has a fifty-two week low of $2.23 and a fifty-two week high of $12.34. The firm has a market cap of $627.86 million, a PE ratio of -2.93 and a beta of 2.96. The business has a 50 day moving average price of $9.93 and a 200-day moving average price of $6.69.

4D Molecular Therapeutics (NASDAQ:FDMT) last announced its quarterly earnings results on Monday, November 10th. The company reported ($1.01) earnings per share for the quarter, beating the consensus estimate of ($1.02) by $0.01. 4D Molecular Therapeutics had a negative net margin of 174,314.17% and a negative return on equity of 47.27%. The business had revenue of $0.09 million during the quarter, compared to analysts’ expectations of $0.40 million. Research analysts predict that 4D Molecular Therapeutics will post -2.84 EPS for the current year.

Insider Buying and Selling

In other 4D Molecular Therapeutics news, insider Scott Bizily sold 2,678 shares of 4D Molecular Therapeutics stock in a transaction that occurred on Friday, October 24th. The stock was sold at an average price of $12.00, for a total transaction of $32,136.00. Following the sale, the insider directly owned 3,594 shares of the company’s stock, valued at approximately $43,128. The trade was a 42.70% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders have sold 10,763 shares of company stock valued at $109,415 in the last ninety days. Company insiders own 9.60% of the company’s stock.

Hedge Funds Weigh In On 4D Molecular Therapeutics

A number of institutional investors have recently added to or reduced their stakes in FDMT. Acadian Asset Management LLC increased its holdings in shares of 4D Molecular Therapeutics by 1,103.4% during the first quarter. Acadian Asset Management LLC now owns 400,606 shares of the company’s stock valued at $1,290,000 after acquiring an additional 367,317 shares in the last quarter. Invesco Ltd. grew its position in 4D Molecular Therapeutics by 318.3% during the 1st quarter. Invesco Ltd. now owns 117,768 shares of the company’s stock valued at $380,000 after purchasing an additional 89,611 shares during the last quarter. Russell Investments Group Ltd. purchased a new stake in 4D Molecular Therapeutics during the 1st quarter valued at about $63,000. Federated Hermes Inc. increased its stake in 4D Molecular Therapeutics by 33,131.8% during the 1st quarter. Federated Hermes Inc. now owns 1,250,181 shares of the company’s stock valued at $4,038,000 after purchasing an additional 1,246,419 shares in the last quarter. Finally, Nuveen LLC purchased a new position in 4D Molecular Therapeutics in the first quarter worth about $486,000. Institutional investors own 99.27% of the company’s stock.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.